Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Azacitidine Dosing in MDS
NCT00102687Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Jan 2005; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00102687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102687.